Examining the Characteristics of Colchicine-Induced Myelosuppression in Clinical Cases: A Systematic Review
Authors' conclusion
Colchicine has few reports of myelosuppression. The majority of patients with myelosuppression had preexisting renal impairment or concomitant CYP3A4 or P-gp inhibitor use.
Study context
- Population
- Patients with myelosuppression from colchicine reported in observational studies or trial data
- Participants
- 47 patients30 studies
- Outcome
- Characteristics of reported colchicine-induced myelosuppressive events
Methodological detailssearches of PubMed, ScienceDirect, Scopus, Embase and Cochrane Library, English-language, references published 1978–2020
- Searches of PubMed, ScienceDirect, Scopus, Embase and Cochrane Library
- English-language
- References published 1978–2020
Pooled result
As reported in the abstract
Characteristics of patients with colchicine-induced myelosuppression
- Renal impairment comorbidity
- 21/47, 44.7%
- Concurrent CYP3A4 inhibitors
- 15 (31.9%)
- Concurrent P-glycoprotein (P-gp) efflux transporter inhibitors
- 13 (27.7%)
- Renal impairment among those taking CYP3A4 inhibitors
- 8/15, 53.3%
- Renal impairment among those taking P-gp inhibitors
- 8/13, 61.5%
- Worsening cytopenia during colchicine use among 21 with renal impairment
- 13
Original publication
Examining the Characteristics of Colchicine-Induced Myelosuppression in Clinical Cases: A Systematic Review. J Rheumatol. Published 1 September 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →